Information Library
Cost control/reduction - Managed Partnerships
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
QUINTILES ANNOUNCES CLINICAL RESEARCH PARNERSHIP WITH THE UNIVERSITY OF PRETORIA
September 10, 2009 – Quintiles Prime Site Program expands into South Africa to accelerate clinical development. -
Anatomy of a Managed Partnership
May 26, 2009
Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs. -
Gain Capital & Retain Value
March 24, 2009
Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product. -
Matching Risks with Rewards
March 24, 2009
A global pharmaceutical company had a new formulation of a core strategic asset half way through its pivotal Phase III studies, but another major product launch at the company was generating such significant expenses that it was squeezing the budget for this and other development programs. -
Reducing Risk
August 1, 2008
A Pharma TV interview with Ben Cons -
The Next Generation of Partnerships
August 1, 2008
A Pharma TV interview with Ben Cons -
Pressures and Opportunities
August 1, 2008
A Pharma TV interview with Ben Cons
Page 1 of 1 (7 items)